Pluristem Therapeutics to Raise $3.0 Million in Registered Direct Offering
BY Business Wire
— 09:55 AM ET 10/06/2009
HAIFA, Israel--(BUSINESS WIRE)-- Pluristem Therapeutics Inc. (PSTI
|
|
Loading... |
|
|
). (NasdaqCM:PSTI) (DAX:PJT) today announced that it has entered into definitive agreements with selected institutional investors to sell common stock and warrants for aggregate gross proceeds of approximately $3.0 million, before deducting placement agent fees and estimated offering expenses. The offering includes 2,702,822 shares of common stock and warrants to purchase 1,081,129 shares of common stock. The price per share of Common Stock is $1.12, and the exercise price of the warrants is $1.60. The Warrants will be exercisable for a period of five years commencing six months following the issuance thereof. The closing is scheduled to take place no later than October 12, 2009.
The offering is made pursuant to the Form S-3 shelf registration statement that was filed by Pluristem with the Securities and Exchange Commission (the “SEC”) and declared effective by the SEC on July 1, 2008. The offering is expected to close on or about October 12, 2009, subject to the satisfaction of customary closing conditions.
Roth Capital Partners, LLC acted as the exclusive placement agent for the offering.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. Any offer will be made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. Copies of the prospectus supplement together with the accompanying prospectus can be obtained at the SEC’s website at http://www.sec.gov or from Roth Capital Partners, 24 Corporate Plaza Drive, Newport Beach, CA, 92660, attention: Equity Capital Markets.